

Supplementary material

Kowalewski M, Gozdek M, Zieliński K, et al. Long-term mortality after percutaneous coronary intervention with drug-eluting stents compared with coronary artery bypass grafting for multivessel and left main disease: a meta-analysis. Kardiol Pol. 2020; 78: 759-761. doi:10.33963/KP.15397.

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1. Randomized controlled trials of PCI DES vs CABG included in the meta-analysis

Study	PRECOMBAT [1]		FREEDOM Follow-On [2]		BEST [3]		NOBLE [4]		SYNTAX Extended Survival [5]		EXCEL [E1]	
	PCI DES	CABG	PCI DES	CABG	PCI DES	CABG	PCI DES	CABG	PCI DES	CABG	PCI DES	CABG
No. of pts.	300	300	478	465	438	442	592	592	903	897	948	957
Age	61.8 (10.0)	62.7(9.5)	63.4 (8.4)	63.0 (9.1)	64.0 (9.3)	64.9 (9.4)	66.2 (9.9)	66.2 (9.4)	65.2 (9.7)	65.0 (9.8)	66.0 (9.6)	65.9 (9.5)
Male (%)	76	77	70.5	67.5	69.4	73.5	80	76	76	79	76.2	77.5
SYNTAX score	24.4 (9.4)	25.8 (10.5)	25.5 (8.5)	26.2 (9.4)	24.2 (7.5)	24.6 (8.1)	22.5 (7.5)	22.4 (8.0)	28.4 (11.5)	29.1 (11.4)	20.6 (6.2)	20.5 (6.1)
EuroSCORE	2.6 (1.8)	2.8 (1.9)	2.5 (2.0)	2.7 (2.2)	2.9 (2.0)	3.0 (2.1)	2.7 (1.5)	2.7 (1.5)	3.8 (2.6)	3.8 (2.7)	NR	NR
Diabetes (%)	34	30	NR	NR	NR	NR	15	15	26	25	30.2	28.0
on insulin (%)	3.3	3.0	31.4	30.3	4.6	4.1	NR	NR	10	10	7.7	7.7
EF (%)	61.7 (8.3)	60.6 (8.5)	NR	NR	59.1 (8.5)	59.9 (8.1)	60.0 (7.4)	58.7 (8.9)	NR	NR	57.0 (9.6)	57.3 (9.0)
EF < 40% (%)	NR	NR	3.3	1.2	NR	NR	NR	NR	1 (<30%)	3 (<30%)	NR	NR
Previous congestive heart failure (%) or NYHA III/IV	0	0.7	NR	NR	3.7	2.7	13.5	18.6	4	5	7.1	6.2
Previous PCI (%)	12.7	12.7	<i>Excluded by design</i>		6.8	8.6	19.6	19.9	<i>Excluded by design</i>		18.4	15.9
Left main disease (%)	100	100	0	0	0	0	100	100	40	39	100	100
Two vessel disease (%)	33.7	30.0	100	100	100	100	NR	NR	31	30	34.3	30.8
Three vessel disease (%)	40.7	41	81.4	82.6	75.3	79.0	NR	NR	60	61	17.2	19.4
No. of lesions (stented)	2.7 (1.4)	NA	3.4 (1.3)	NA	3.4 (1.4)	NA	2.0 (1.5)	NA	NR	NA	1.7 (0.8)	NA
No. of lesions (grafted)	NA	2.7 (0.9)	NA	2.9 (0.8)	NA	3.1 (0.9)	NA	2.3 (0.7)	NA	NR	NA	2.6 (0.8)
Use of LIMA (%)	NA	93.6	NA	94.3	NA	99.3	NA	NR	NA	NR	NA	98.8
Complete revascularization (%)	68.3	70.3	NR	NR	50.9	71.5	NR	NR	NR	NR	NR	NR
Median follow-up	11.3 years		7.5 years		4.6 years*		4.9 years*		11.2 years		5.0 years**	
Study quality	High		High		High		High		High		High	

*Kaplan Meier estimates for 5.0 years

**93.2% patients in the PCI group and 90.1% in the CABG group completed 5 years of follow-up

PCI, percutaneous coronary intervention; DES, drug eluting stent; CABG, coronary artery bypass grafting; PRECOMBAT, Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease trial; FREEDOM, Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease trial; BEST; The Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery Disease trial; NOBLE; Nordic-Baltic-British Left Main Revascularization Study; SYNTAX, The Synergy between PCI with Taxus and Cardiac Surgery; EXCEL, Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization trial; EF, ejection fraction; NR, not reported; NA, not available.

Figure S1. Visual analysis of publication bias.

